You are here

Genentech

Two Genentech vets reunite at Immune-Onc to help steer its $33M drive to the clinic

Two Genentech vets reunite at Immune-Onc to help steer its $33M drive to the clinic

Endpoints

Flag link:

Genentech and Hemophilia Patients Eye Oct. 4 for Hemlibra Ruling

Genentech and Hemophilia Patients Eye Oct. 4 for Hemlibra Ruling

BioSpace

Flag link:

Roche's Child Arthritis Drug's New Formulation Gets FDA Nod

Roche's Child Arthritis Drug's New Formulation Gets FDA Nod

Yahoo/Zacks.com

systematic juvenile idiopathic arthritis

Flag link:

Roche CEO Severin Schwan is keeping his hand on the budget ax

Roche CEO Severin Schwan is keeping his hand on the budget ax

Endpoints

Flag link:

New Flu Season, New Flu Drug from Genentech

New Flu Season, New Flu Drug from Genentech

BioSpace

Flag link:

In a rare delay for the fast PD-1/L1 crowd, FDA tells Roche to wait on its Tecentriq/Avastin triple for lung cancer

In a rare delay for the fast PD-1/L1 crowd, FDA tells Roche to wait on its Tecentriq/Avastin triple for lung cancer

Endpoints

Flag link:

Pfizer Calls for FDA Guidance to Address False and Misleading Biosimilar Ads

Pfizer Calls for FDA Guidance to Address False and Misleading Biosimilar Ads

RAPS.org

Flag link:

Affimed and Roche ink $5bn plus cancer immunotherapy deal

Affimed and Roche ink $5bn plus cancer immunotherapy deal

Pharmaforum

cancer immunotherapy

drug development

Flag link:

As biosimilars loom, Roche's Genentech plans to lay off 223 staffers in California

As biosimilars loom, Roche's Genentech plans to lay off 223 staffers in California

Fierce Pharma

Flag link:

Genentech, Horizon Earn Spots on List of ‘Companies That Care’

Genentech, Horizon Earn Spots on List of ‘Companies That Care’

BioSpace

Flag link:

Roche vaults into lead in frontline triple negative breast cancer as Tecentriq/Abraxane combo aces progression-free survival

Roche vaults into lead in frontline triple negative breast cancer as Tecentriq/Abraxane combo aces progression-free survival

Endpoints

triple negative breast cancer

Flag link:

Microbiome report for week ending 6-24-18

Microbiome report for week ending 6-24-18

CP Wire

Axial Biotherapeutics

Flag link:

Microbiome report for week ending 6-24-18

Axial Biotherapeutics

Flag link:

FDA Approves Genentech’s Rituxan For Rare Autoimmune Disease Pemphigus Vulgaris

FDA Approves Genentech’s Rituxan For Rare Autoimmune Disease Pemphigus Vulgaris

CP Wire

pemphigus vulgaris

Genentech/Roche

Flag link:

Genentech signs $534M deal with Microbiotica to search gut bacteria for IBD targets, new drugs

Genentech signs $534M deal with Microbiotica to search gut bacteria for IBD targets, new drugs

Fierce Biotech

Flag link:

Roche Up, J&J Down as Cancer Drug Combos Yield More Mixed Results

Roche Up, J&J Down as Cancer Drug Combos Yield More Mixed Results

Xconomy

clinical trials

Flag link:

Genentech allies with a metagenomics upstart in New York on a discovery deal jam packed with biobucks

Genentech allies with a metagenomics upstart in New York on a discovery deal jam packed with biobucks

Endpoints

Lodo Therapeutics

Flag link:

FDA promises Roche a snap decision on Tecentriq triple for frontline lung cancer as it falls even further behind Merck, Bristol-Myers

FDA promises Roche a snap decision on Tecentriq triple for frontline lung cancer as it falls even further behind Merck, Bristol-Myers

Endpoints

Flag link:

Genentech antibody spotlights new target for antibiotic-resistant bacteria

Genentech antibody spotlights new target for antibiotic-resistant bacteria

Fierce Biotech

antibiotic resistance

Flag link:

After FDA setback, Bellicum bolsters R&D team with ex-Genentech executive

After FDA setback, Bellicum bolsters R&D team with ex-Genentech executive

Fierce Biotech

Flag link:

Pages